ENIMMUNE CORP. is a Taiwan-based biotechnology new drug company mainly engaged in the development, produce and distribution of new drugs. The Company's new drug products include biological agents, monoclonal antibodies, vaccines, and small molecule drugs. The Company mainly conducts drug testing business, biotechnology service business, international trade business, western medicine wholesale and retail business. The product is Tuberculin PPD.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
22/26/22	NT$16.05	+0.63%	57,451
21/26/21	NT$15.95	-0.93%	14,304
20/26/20	NT$16.10	-1.23%	26,316
19/26/19	NT$16.30	-0.31%	54,499
16/26/16	NT$16.35	+0.93%	1,19,953

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 22/10/2026			5-day change	1st Jan Change
16.05 ^TWD	+0.63%		-0.93%	-22.09%

15/10	Duopharma Biotech Berhad Signs Five-Year Exclusive Distribution Agreement with Enimmune Corporation in Malaysia	CI
12/08	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Market Cap	115.78Cr 3.55Cr 3.17Cr 2.92Cr 2.66Cr 4.98Cr 336.27Cr 5.06Cr 35Cr 14Cr 176.18Cr 13Cr 13Cr 558.11Cr	P/E 2024	-11.3x	P/E 2025	-9.04x
Enterprise Value	110.32Cr 3.38Cr 3.02Cr 2.79Cr 2.53Cr 4.75Cr 320.41Cr 4.82Cr 34Cr 13Cr 167.87Cr 13Cr 12Cr 531.79Cr	EV / Sales 2024	35.4x	EV / Sales 2025	29.7x
Free-Float	28.72%	Yield 2024 *	-	Yield 2025	-

15/10	Duopharma Biotech Berhad Signs Five-Year Exclusive Distribution Agreement with Enimmune Corporation in Malaysia	CI
12/08	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08/04	Enimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
13/25/13	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2025	CI
18/25/18	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2024	CI
13/24/13	Enimmune corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
13/24/13	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
11/23/11	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2023	CI
21/23/21	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
15/22/15	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2022	CI
26/22/26	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2021	CI
14/21/14	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2021	CI
22/21/22	Enimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	CI

1 day	+0.63%
1 week	-0.93%
Current month	-0.62%
1 month	-0.62%
3 months	-4.46%
6 months	-17.48%
Current year	-22.09%

Enimmune corporation Share Price

Stocks

6564

TW0006564008

Biotechnology & Medical Research

Valuation: Enimmune corporation

Chart: Enimmune corporation

Latest news: Enimmune corporation

Quotes and Performance

Price Extremes

Managers and Directors: Enimmune corporation

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 week	15.65	16.45
1 month	15.4	17.05
Current year	14.9	22.15
1 year	14.9	22.65
3 years	14.65	49.3
5 years	14.65	75.3
10 years	14.49	125

Manager	Title	Age	Since
Che Wei Chang CEO	Chief Executive Officer	-	07/01/2019
Ching Fen Yang CTO	Chief Tech/Sci/R&D Officer	-	21/07/2014
Hung Tun Chen AUD	Comptroller/Controller/Auditor	-	-

Director	Title	Age	Since
Chung Cheng Liu CHM	Chairman	-	07/01/2019
Fei Pan BRD	Director/Board Member	-	02/01/2014
Chin Yi Chiu BRD	Director/Board Member	-	19/05/2015

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENIMMUNE CORPORATION	+0.63%	-0.93%	-31.12%	-55.91%	3.55Cr
WUXI APPTEC CO., LTD.	-4.10%	-8.54%	+40.05%	+66.99%	6.33TCr
ARGENX SE	-0.41%	+3.27%	+10.46%	+72.82%	5.49TCr
LONZA GROUP AG	+0.74%	+4.04%	+12.18%	+88.71%	5.33TCr
IQVIA HOLDINGS INC.	+0.61%	+2.69%	+27.75%	+50.97%	4.58TCr
BEONE MEDICINES AG	-1.08%	+2.19%	+21.92%	+131.38%	4.35TCr
REVOLUTION MEDICINES, INC.	-3.39%	-0.83%	+254.27%	+571.04%	4.02TCr
CELLTRION, INC.	-1.67%	+6.70%	+14.42%	+56.67%	3.35TCr
WUXI BIOLOGICS (CAYMAN) INC.	+1.90%	-4.56%	+29.58%	-0.33%	2.37TCr
GENMAB A/S	+1.30%	+4.94%	+38.23%	+28.59%	2.38TCr
Average	-0.57%	+0.77%	+41.77%	+101.09%	3.82TCr
Weighted average by Cap.	-1.01%	+0.89%	+47.92%	+121.88%

	2024	2025
Net sales	3.99Cr 12.24L 10.92L 10.08L 9L 17.18L 12Cr 17.44L 1.21Cr 47.83L 6.07Cr 45.94L 44.96L 19Cr	4.82Cr 14.78L 13.19L 12.17L 11.06L 20.74L 14Cr 21.06L 1.47Cr 57.75L 7.33Cr 55.47L 54.28L 23Cr
Net income	-16Cr -48.31L -43.12L -39.78L -36.14L -67.8L -46Cr -68.84L -4.79Cr -1.89Cr -24Cr -1.81Cr -1.77Cr -76Cr	-16Cr -50.39L -44.98L -41.5L -37.7L -70.73L -48Cr -71.81L -5Cr -1.97Cr -25Cr -1.89Cr -1.85Cr -79Cr
Net Debt	-38Cr -1.17Cr -1.05Cr -96.45L -87.63L -1.64Cr -110.95Cr -1.67Cr -12Cr -4.58Cr -58Cr -4.4Cr -4.3Cr -184.15Cr	-5.46Cr -16.74L -14.94L -13.78L -12.52L -23.49L -16Cr -23.86L -1.66Cr -65.42L -8.31Cr -62.84L -61.49L -26Cr